# South America hERG Screening Market > South America hERG screening Market Research Report By Type (Gene KCNH2, Mutant KCNH2), By Ion Channel (Voltage Gated, Ligand Gated), By Application (Antiarrhythmic, Antipsychotic, Antibiotics, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.63% - **2024:** $ 56 Million - **2025:** $ 61.95 Million - **2035:** $ 170.2 Million - **Key Players:** Thermo Fisher Scientific (US), Charles River Laboratories (US), Eurofins Scientific (LU), Celerion (US), CROMSOURCE (IT), Inotiv (US), Celerion (US), Celerion (US) **Report ID:** MRFR/HC/51280-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-herg-screening-market-53041 --- ## Market Summary ## **South America****hERG****S****creening****Market****Overview** As per MRFR analysis, the South America hERGScreening Market Size was estimated at 80 (USD Million) in 2023. The South America hERG screening Market Industry is expected to grow from 89.6(USD Million) in 2024 to 287.18 (USD Million) by 2035. The South America hERG screening Market CAGR (growth rate) is expected to be around 11.17% during the forecast period (2025 - 2035). ## **Key****South America****hERG****S****creening****Market****Trends Highlighted** The South America hERG Screening Market is currently characterized by a number of significant trends that are being driven by the growing demand for safer pharmaceuticals. Regulatory entities in countries such as Brazil and Argentina have prioritized comprehensive hERG screening as a component of the drug approval process in response to the increasing recognition of the significance of cardiac safety in drug development. This regulatory focus is a critical market driver, motivating biopharmaceutical companies to invest in sophisticated screening technologies to guarantee patient safety and promote compliance.  Additionally, the increasing incidence of cardiovascular diseases in South America is compelling pharmaceutical companies to prioritize HERG channel testing. The robust investment in healthcare infrastructure in the region is creating opportunities to enhance research and development capabilities, which can assist in the promotion of innovation in drug testing. In HERG testing, there has been a recent trend toward automation and high-throughput screening methods, which has enabled the evaluation of compound safety at a quicker and more cost-effective pace.  These methods are becoming more accessible to small and medium enterprises within the industry, which were previously constrained by resource constraints, thanks to regional technological advancements. Furthermore, the research capabilities of South America are being further enhanced by the increasing number of collaborations between the public and private sectors. There is a growing opportunity to incorporate hERG screening into the development of targeted therapies as the interest in personalized medicine continues to grow. The emphasis on integrated approaches that integrate HERG testing with other cardiotoxicity assessments is also gathering traction, resulting in a comprehensive strategy for drug safety assessment.  In general, the South American hERG screening Market is on the cusp of a substantial transformation, which will enable the development of safer drugs and the enhancement of healthcare outcomes for the general public. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **South America****hERG****S****creening****Market****Drivers** Increase in Cardiovascular Diseases The South America [hERG screening](../../../reports/herg-screening-market-10386) Market Industry is expected to witness significant growth due to the rising incidences of cardiovascular diseases across the region. According to the Pan American Health Organization, cardiovascular diseases account for approximately 30% of all deaths in South America, highlighting a critical health concern. As the need for precise and effective screening methods increases, organizations such as the Brazilian Society of Cardiology are actively advocating for improved diagnostic technologies. This increased awareness and need for accurate HERG screening can drive the market upwards, as healthcare providers aim to adopt comprehensive screening solutions to enhance patient outcomes and reduce the economic burden associated with cardiovascular diseases. Growing Pharmaceutical Research and Development Activities The South America hERG screening Market Industry is propelled by a surge in pharmaceutical Research and Development activities focusing on drug safety and efficacy. With the rise of global pharmaceutical companies establishing research facilities in countries like Brazil and Argentina, the demand for HERG screening is on the rise. Notably, the National Agency of Sanitary Surveillance of Brazil has issued guidelines emphasizing the importance of HERG channel testing in new drug approvals, which aligns with a projected increase in new drug applications. This strategic focus on rigorous testing has become essential for successful drug development, as it helps in identifying potential risks associated with drug compounds early in the process. Technological Advancements in Screening Technologies Technological advancements in screening technologies are driving the South America hERG screening Market Industry towards growth. Innovative solutions such as high-throughput screening and automated platforms are being developed, which significantly reduce the time and resources required for HERG screening. The Brazilian Institute of Science and Technology has reported an increase in the adoption of these advanced technologies in laboratories across the region, enabling accurate and efficient testing. As regulatory bodies continue to emphasize rapid testing and the need for quality data to ensure patient safety, the demand for advanced HERG screening tools will continue to grow, thereby fueling market development. Regulatory Support and Guidelines Regulatory support and guidelines play a crucial role in the growth of the South America hERG screening Market Industry. Health authorities in countries such as Argentina and Colombia have begun implementing stringent regulatory frameworks that emphasize the necessity of HERG screening for new pharmaceutical products. For instance, the Argentine Drug Authority has outlined specific requirements for HERG testing in their drug approval process, compelling pharmaceutical companies to ensure their products pass this vital safety assessment.  The encouragement from regulatory bodies not only enforces compliance but also boosts market growth as it instills trust among end-users in the safety and efficacy of new therapies. ## **South America****hERG****S****creening****Market****Segment Insights** ### **hERG****S****creening****Market****Type Insights** The South America hERG screening Market is witnessing significant growth, particularly in its Type segmentation, which includes Gene KCNH2 and Mutant KCNH2. The Gene KCNH2 segment is crucial as it deals with the genetic factors influencing cardiac repolarization and ion channel functionality, essential for understanding various cardiac disorders. As awareness of genetic implications in health increases, this segment plays an important role in the development of tailored therapeutic approaches. Mutant KCNH2, on the other hand, signifies variants in the KCNH2 gene that can lead to arrhythmias and other cardiac problems. The prominence of this segment stems from the growing need for accurate diagnostic tools to identify at-risk populations. With an increasing focus on precision medicine and personalized care in South America, innovations in HERG screening are becoming invaluable for healthcare providers and pharmaceutical companies alike. Furthermore, the regulatory environment is gradually evolving to adapt to these emerging technologies, fostering opportunities for growth and development in this segment. The ongoing research and significant investments in genetic testing and HERG screening technologies enhance the efficacy of treatment options and improve patient outcomes. Overall, the emphasis on genetic components in the HERG screening Market aligns well with the regional health priorities, making the Type segmentation a vital aspect in the medical landscape of South America. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **hERG****S****creening****Market****Ion Channel Insights** The Ion Channel segment within the South America hERG screening Market plays a crucial role in understanding cardiac safety and drug development. This segment is primarily divided into voltage-gated and ligand-gated channels, each contributing distinctly to pharmaceutical research. Voltage-gated channels are essential in regulating neuronal and muscle excitability, making them significant for drugs targeting conditions such as epilepsy and cardiac arrhythmias. Similarly, ligand-gated channels are vital for synaptic transmission and play a critical role in neurotransmission. The growth of the healthcare sector in South America, fueled by advancements in Research and Development and increased investment in biotechnology, enhances the importance of these Ion Channel screening methods. Moreover, the rising demand for efficient drug screening techniques drives the development of innovative platforms that leverage these channel types, reflecting the increasing focus on patient safety and regulatory compliance in the region. Overall, this segment is positioned to contribute significantly to the evolving landscape of drug discovery in South America. ### **hERG****S****creening****Market****Application Insights** The South America HERG screening Market, focusing on the Application segment, showcases significant growth driven by various therapeutic areas. Within this landscape, the Antiarrhythmic application plays a crucial role in ensuring safe drug development due to its impact on cardiac safety assessments, reflecting the increasing demand for effective treatment of arrhythmias. The Antipsychotic category is also noteworthy, as it addresses mental health challenges prevalent in the region, emphasizing the need for robust screening methods to mitigate adverse cardiac effects commonly associated with psychiatric medications. Antibiotics represent another vital aspect of HERG screening, underscoring the importance of evaluating cardiac safety as antibiotic use continues to evolve, especially in combating resistant strains. Other applications within the market contribute to a diversified approach to drug safety, catering to emerging therapeutic areas and technological advancements in drug development. The South America hERG screening Market is thus witnessing a blend of traditional and innovative applications, highlighting the importance of comprehensive safety evaluations to align with regional healthcare demands. ### **hERG****S****creening****Market****Regional Insights** The South America hERG screening Market is experiencing significant growth, driven by the need for advanced pharmacological safety assessments in the region. Brazil, as a major player, holds a significant share in the market and is pivotal due to its large pharmaceutical industry, increasing investments in Research and Development, and an expanding healthcare sector. Mexico also plays a crucial role, benefiting from its strategic location and improvements in healthcare infrastructures that enhance drug screening processes. Argentina, while smaller, demonstrates growth potential in HERG screening due to rising awareness of drug safety and regulatory compliance. The Rest of South America, although less dominant, is gradually emerging as a developing hub for HERG screening technologies, influenced by growing demand for safer therapeutic drugs and increased adoption of innovative healthcare solutions. The region is witnessing trends such as collaboration between public and private sectors aimed at improving drug safety, further propelling the growth of the South America hERG screening Market through enhanced technological capabilities and regulatory frameworks. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **South America****hERG****S****creening****Market****Key Players and Competitive Insights:** The South America hERG screening Market is witnessing notable expansion, driven by the increasing prevalence of cardiac-related disorders and a growing need for effective drug safety testing. The competition within this market is characterized by a mix of established players and emerging companies, all vying to capture market share as awareness of the HERG channel's significance in pharmaceuticals continues to rise. The demand for efficient HERG screening technologies has also increased, given the stringent regulatory environments and the emphasis on patient safety. This landscape is constantly evolving, presenting both opportunities and challenges for market participants. Innovations in technology and research capabilities are essential for firms to maintain a competitive edge in this growing market. Abbott Laboratories stands out in the South American HERG screening Market, showcasing substantial strengths that fortify its competitive positioning. The company has a significant market presence bolstered by its commitment to research and development, which enables Abbott Laboratories to offer advanced screening technologies and robust testing solutions tailored for the unique demands of the South American healthcare landscape. Their established reputation for quality and reliability further enhances their attractiveness to pharmaceutical companies seeking comprehensive screening methodologies. Abbott's effective collaborations with local research institutions and healthcare organizations have also contributed to their strong foothold in the region, enabling them to identify market opportunities and develop tailored service offerings that cater to specific regional needs. Pfizer remains a key player in the South America HERG screening Market, leveraging a robust portfolio of products and services that focus on enhancing drug safety and efficacy. The company’s commitment to innovation facilitates the development of groundbreaking HERG screening technologies that meet regulatory standards while addressing the local market's specific requirements. Pfizer's strengths lie not only in its comprehensive testing services but also in its strategic alliances and partnerships within the region, which enhance its market reach and operational capabilities.  The company's active participation in mergers and acquisitions further positions it advantageously in the competitive landscape, as these strategic moves allow for the integration of advanced technologies and expansion of its service offerings. Overall, Pfizer maintains a strong influence in South America by consistently evolving to meet the challenges posed by the dynamic healthcare environment in the region. **Key Companies in the****South America****hERG****S****creening****Market****Include:** **South America****hERG****S****creening****Market****Developments** Recent developments in the South America hERG screening Market indicate a growing emphasis on safety pharmacology as drug manufacturers in the region focus on compliance with international regulations. Notably, Abbott Laboratories and Pfizer are involved in enhancing their respective HERG screening processes to ensure cardiovascular safety for new drug candidates. In July 2023, Roche announced a partnership with a local biotechnology firm to improve drug testing capabilities. Thermo Fisher Scientific has expanded its service offerings in Brazil to cater to the rising demand for HERG screening services. Financial growth is evident, with market valuations for companies like Celerion and Fujifilm experiencing a notable increase due to investments in innovative screening technologies.  In terms of mergers and acquisitions, AstraZeneca's acquisition of a small biotech firm in June 2023 has strengthened its research capabilities in pharmacology within the South American market. Major happenings in recent years include Sanofi's establishment of a new research center in Argentina in August 2022, focusing on drug safety evaluations, underlining the importance placed on HERG screening within the regulatory framework of the region. The ongoing developments cater to an evolving landscape where drug safety is becoming increasingly prioritized in South America. ## **South America****hERG****S****creening****Market****Segmentation Insights** ### **hERG****S****creening****Market****Type****Outlook** ### **h****ERG****S****creening****Market****Ion Channel****Outlook** ### **h****ERG****S****creening****Market****Application****Outlook** ### **h****ERG****S****creening****Market****Regional****Outlook** ## Market Drivers ### Rising Cardiovascular Disease Incidence The increasing prevalence of cardiovascular diseases in South America is a crucial driver for the herg screening market. As healthcare providers focus on improving patient outcomes, the demand for effective screening methods has surged. Reports indicate that cardiovascular diseases account for approximately 30% of all deaths in the region, prompting regulatory bodies to emphasize cardiac safety in drug development. This heightened awareness has led to a growing need for herg screening solutions, as pharmaceutical companies seek to mitigate risks associated with drug-induced arrhythmias. Consequently, the herg screening market is likely to experience significant growth as stakeholders prioritize patient safety and regulatory compliance. ### Investment in Biopharmaceutical Research The herg screening market is witnessing a surge in investment from biopharmaceutical companies in South America. With the region's growing focus on innovative drug development, there is an increasing need for robust screening methods to ensure cardiac safety. In 2025, biopharmaceutical investments in South America are projected to reach $5 billion, reflecting a commitment to enhancing research capabilities. This influx of funding is likely to drive the adoption of advanced herg screening technologies, as companies aim to streamline their drug development processes while adhering to stringent regulatory requirements. As a result, the herg screening market stands to benefit from this trend, fostering innovation and improving patient safety. ### Growing Awareness of Drug-Induced Arrhythmias The herg screening market is experiencing growth due to the increasing awareness of drug-induced arrhythmias among healthcare professionals and regulatory bodies in South America. As the understanding of the risks associated with certain medications expands, there is a heightened emphasis on cardiac safety during drug development. This awareness is reflected in the rising number of training programs and workshops focused on herg screening methodologies. In 2025, it is anticipated that educational initiatives will increase by 15%, further promoting the importance of herg screening in ensuring patient safety. Consequently, the herg screening market is likely to benefit from this trend, as stakeholders prioritize effective screening practices. ### Technological Integration in Drug Development The herg screening market is being propelled by the integration of advanced technologies in drug development processes across South America. The adoption of high-throughput screening methods and automated systems is enhancing the efficiency and accuracy of herg screening. In 2025, it is projected that the market for automated screening technologies will grow by 25%, reflecting the industry's shift towards more sophisticated methodologies. This technological advancement not only streamlines the screening process but also reduces the time and costs associated with drug development. As a result, the herg screening market is likely to see increased investment and innovation, ultimately benefiting patient safety and therapeutic efficacy. ### Regulatory Changes and Compliance Requirements Recent regulatory changes in South America have significantly impacted the herg screening market. Authorities are increasingly mandating comprehensive cardiac safety assessments for new drug applications, which has heightened the demand for herg screening solutions. In 2025, it is estimated that compliance costs for pharmaceutical companies could rise by 20% due to these new regulations. This shift necessitates the integration of herg screening into the drug development pipeline, compelling companies to invest in advanced technologies and methodologies. As a result, the herg screening market is poised for growth, driven by the need for compliance and the assurance of patient safety in drug therapies. ## Future Outlook The [HERG Screening Market](https://www.marketresearchfuture.com/reports/herg-screening-market-10386) is projected to grow at a 10.63% CAGR from 2025 to 2035, driven by increasing regulatory demands and technological advancements. **New opportunities:** - Development of AI-driven screening technologies for enhanced accuracy. - Expansion of partnerships with pharmaceutical companies for integrated testing solutions. - Launch of mobile herg screening units for remote testing capabilities. By 2035, the herg screening market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Cardiovascular Research (Largest) vs. Drug Development (Fastest-Growing) In the South America HERG screening market, Cardiovascular Research stands out as the largest segment, reflecting a significant focus on understanding heart-related conditions and the impact of drugs on cardiac cells. This sector accounts for a considerable portion of the market share due to the increasing incidence of cardiac diseases and the rising demand for tailored therapies. Conversely, Drug Development is emerging rapidly, driven by the need for innovative pharmaceutical solutions that ensure drug safety and efficacy, particularly concerning cardiac health. Cardiovascular Research: Dominant vs. Drug Development: Emerging Cardiovascular Research holds a dominant position in the South America HERG screening market, primarily due to the critical emphasis on understanding drug interactions at the cardiac level. This segment focuses on ensuring the safety of compounds being developed for cardiovascular indications, thereby significantly influencing pharmaceutical strategies. On the other hand, Drug Development is recognized as an emerging segment, fueled by technological advancements in screening methodologies and a heightened regulatory focus on drug safety. This segment's growth is propelled by an increasing collaboration between biotech firms and academic institutions, aiming to develop safer, more effective therapeutic options. ### By End Use: Pharmaceutical Companies (Largest) vs. Contract Research Organizations (Fastest-Growing) In the South America Herg Screening market, pharmaceutical companies hold the largest market share, driven by their extensive research and development activities. These companies are focused on developing novel therapies, leading to a consistent demand for Herg screening services. In contrast, contract research organizations (CROs) are rapidly gaining market share as they provide specialized outsourced services to the pharmaceutical industry, making them a crucial player in the landscape. Pharmaceutical Companies (Dominant) vs. Contract Research Organizations (Emerging) Pharmaceutical companies are dominant in the South America Herg screening market due to their robust investment in drug development and regulatory compliance. These companies leverage Herg screening to ensure the safety and efficacy of their products, thus establishing competitive advantages. On the other hand, contract research organizations are emerging as vital partners for pharmaceutical firms, offering flexible and scalable solutions for preclinical and clinical trials. As the demand for innovative therapies grows, CROs are expected to expand rapidly, driven by their ability to adapt to the evolving needs of the pharmaceutical sector. ### By Technology: Automated Screening Systems (Largest) vs. High-Throughput Screening (Fastest-Growing) In the South America HERG screening market, the Automated Screening Systems hold the largest market share, driven by their efficiency and ability to deliver rapid results. This segment is crucial for pharmaceutical companies focusing on drug safety and efficacy. In contrast, High-Throughput Screening, while currently smaller in market share, is recognized for its potential to speed up the drug discovery process significantly and is gaining traction among biotech firms due to the rising demand for faster testing methods. Automated Screening Systems: Dominant vs. High-Throughput Screening: Emerging Automated Screening Systems are the backbone of the HERG screening process in South America, favored for their precision and speed in evaluating drug effects on cardiac cells. These systems allow researchers to process millions of samples quickly, which is essential in the fast-paced pharmaceutical environment. High-Throughput Screening, emerging as a revolutionary approach, enables comprehensive testing with reduced resource expenditure. As research laboratories continuously seek more efficient methodologies, High-Throughput Screening is expected to capture a growing share of the market, appealing to organizations eager for innovation in drug screening. ### By Test Type: Voltage Clamp Assays (Largest) vs. Patch Clamp Techniques (Fastest-Growing) In the South America HERG screening market, Voltage Clamp Assays dominate with a significant market share due to their ability to provide accurate and reliable ion channel characterization. These assays are extensively utilized in drug development and safety pharmacology, leading them to maintain a strong foothold in the market. In contrast, Patch Clamp Techniques are emerging rapidly, gaining traction among researchers and pharmaceutical companies. Their advanced precision in recording ionic currents makes them increasingly preferred, driving their share to grow significantly in recent years. The acceleration in the growth of the Patch Clamp Techniques segment can be attributed to advancements in technology and increasing investments in drug research and development. Companies are recognizing the importance of understanding cardiac safety, contributing to a rising demand for robust screening methods that these techniques provide. As researchers continue to seek innovative solutions, the adoption of Patch Clamp Techniques is poised to flourish, complemented by training programs and workshops that enhance proficiency among scientists in South America. Voltage Clamp Assays (Dominant) vs. Current Clamp Assays (Emerging) Voltage Clamp Assays hold a dominant position in the South America HERG screening market due to their established efficacy in evaluating ion channel behavior under controlled voltage conditions. These assays allow for a detailed understanding of drug interactions with HERG channels, crucial for assessing cardiotoxicity risk. On the other hand, Current Clamp Assays represent an emerging alternative that is gaining attention for their ability to record the membrane potential and action potentials of cells. Though currently less prevalent than Voltage Clamp Assays, Current Clamp Assays are becoming popular among researchers who seek insights on cellular electrophysiology, particularly for their applications in the evaluation of neuronal networks and cardiac cell functionality. As scientific understanding evolves, these emerging technologies are likely to gain greater acceptance. ## Regional Market Share Analysis ### Mexico : Regulatory Support Fuels Growth With a market share of 10.5%, Mexico's herg screening market is gaining traction, driven by government initiatives aimed at boosting healthcare innovation. The demand for herg screening is increasing due to the growing pharmaceutical industry and rising awareness of drug safety. Regulatory bodies are enhancing frameworks to support clinical trials, which is vital for market expansion. The country's investment in healthcare infrastructure further bolsters this growth. ### Argentina : Pharmaceutical Growth Drives Market Argentina accounts for 12.9% of the South American herg screening market, reflecting a growing demand for drug safety testing. The pharmaceutical sector is expanding, supported by government incentives for research and development. Regulatory frameworks are evolving to ensure compliance with international standards, enhancing market attractiveness. The increasing prevalence of chronic diseases is also driving the need for effective drug testing solutions. ### Rest of South America : Potential for Herg Screening Growth The Rest of South America holds a 7.0% market share in the herg screening sector, with varying demand across countries. Key growth drivers include increasing healthcare investments and a focus on improving drug safety regulations. Countries like Chile and Colombia are emerging as significant players, with supportive government policies fostering innovation. The competitive landscape features both local and international players, enhancing market dynamics. ## Competitive Benchmarking The herg screening market in South America is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Thermo Fisher Scientific (US), Charles River Laboratories (US), and Eurofins Scientific (LU) are at the forefront, each adopting distinct strategies to enhance their market presence. Thermo Fisher Scientific (US) focuses on technological advancements in screening methodologies, while Charles River Laboratories (US) emphasizes its comprehensive service offerings, including preclinical and clinical development. Eurofins Scientific (LU) appears to be leveraging its extensive laboratory network to optimize service delivery across the region, thereby enhancing its competitive edge. Collectively, these strategies contribute to a dynamic environment where innovation and service diversification are paramount.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to better serve the South American market. The competitive structure of the herg screening market is moderately fragmented, with several players vying for market share. This fragmentation allows for a variety of service offerings, yet the influence of major players remains significant, as they set benchmarks for quality and innovation that smaller firms often strive to meet. In October Thermo Fisher Scientific (US) announced the launch of a new high-throughput herg screening platform designed to enhance drug safety assessments. This strategic move is likely to position the company as a leader in the market, as it addresses the growing demand for efficient and reliable screening solutions. The introduction of this platform not only reflects Thermo Fisher's commitment to innovation but also aligns with the industry's shift towards more automated and scalable solutions. In September Charles River Laboratories (US) expanded its partnership with a leading pharmaceutical company to provide integrated herg screening services. This collaboration is indicative of Charles River's strategy to deepen its service offerings and enhance its value proposition to clients. By aligning with a major player in the pharmaceutical sector, Charles River is likely to strengthen its market position and drive revenue growth through increased service utilization. In August Eurofins Scientific (LU) acquired a regional laboratory specializing in herg screening, thereby expanding its operational footprint in South America. This acquisition not only enhances Eurofins' capabilities but also allows for greater market penetration. The strategic importance of this move lies in Eurofins' ability to offer localized services, which can significantly improve turnaround times and customer satisfaction. As of November the herg screening market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) into screening processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas may gain a substantial advantage in the market. ## Recent News & Developments Recent developments in the South America hERG screening Market indicate a growing emphasis on safety pharmacology as drug manufacturers in the region focus on compliance with international regulations. Notably, Abbott Laboratories and Pfizer are involved in enhancing their respective HERG screening processes to ensure cardiovascular safety for new drug candidates. In July 2023, Roche announced a partnership with a local biotechnology firm to improve drug testing capabilities. Thermo Fisher Scientific has expanded its service offerings in Brazil to cater to the rising demand for HERG screening services. Financial growth is evident, with market valuations for companies like Celerion and Fujifilm experiencing a notable increase due to investments in innovative screening technologies.  In terms of mergers and acquisitions, AstraZeneca's acquisition of a small biotech firm in June 2023 has strengthened its research capabilities in pharmacology within the South American market. Major happenings in recent years include Sanofi's establishment of a new research center in Argentina in August 2022, focusing on drug safety evaluations, underlining the importance placed on HERG screening within the regulatory framework of the region. The ongoing developments cater to an evolving landscape where drug safety is becoming increasingly prioritized in South America. ## **South America****hERG****S****creening****Market****Segmentation Insights** ### **hERG****S****creening****Market****Type****Outlook** ### **h****ERG****S****creening****Market****Ion Channel****Outlook** ### **h****ERG****S****creening****Market****Application****Outlook** ### **h****ERG****S****creening****Market****Regional****Outlook** ## Report Scope | MARKET SIZE 2024 | 56.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 61.95(USD Million) | | MARKET SIZE 2035 | 170.2(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.63% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Charles River Laboratories (US), Eurofins Scientific (LU), Celerion (US), CROMSOURCE (IT), Inotiv (US), Celerion (US), Celerion (US) | | Segments Covered | Type, Ion Channel, Application | | Key Market Opportunities | Emerging technologies enhance herg screening efficiency, addressing regulatory demands and safety concerns in drug development. | | Key Market Dynamics | Rising regulatory scrutiny drives demand for advanced human ether-a-go-go related gene screening technologies in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the current valuation of the South America HERG screening market?** A: As of 2024, the South America HERG screening market was valued at 56.0 USD Million. **Q: What is the projected market valuation for the South America HERG screening market by 2035?** A: The market is projected to reach a valuation of 177.24 USD Million by 2035. **Q: What is the expected CAGR for the South America HERG screening market during the forecast period?** A: The expected CAGR for the South America HERG screening market from 2025 to 2035 is 11.04%. **Q: Which companies are considered key players in the South America HERG screening market?** A: Key players include Thermo Fisher Scientific, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories. **Q: What are the primary applications of HERG screening in South America?** A: The primary applications include Drug Development, Toxicology Studies, Cardiovascular Research, and Safety Pharmacology. **Q: How do pharmaceutical companies contribute to the HERG screening market?** A: Pharmaceutical companies are projected to account for 20.0 to 60.0 USD Million in market valuation. **Q: What technologies are utilized in HERG screening?** A: Technologies include Automated Screening Systems, Manual Screening Methods, and High-Throughput Screening. **Q: What test types are commonly used in HERG screening?** A: Common test types include Voltage Clamp Assays, Current Clamp Assays, and Patch Clamp Techniques. **Q: What role do Contract Research Organizations play in the HERG screening market?** A: Contract Research Organizations are expected to contribute between 15.0 and 45.0 USD Million to the market. **Q: What is the significance of the projected growth in the HERG screening market?** A: The projected growth indicates a rising demand for HERG screening, reflecting advancements in drug safety and efficacy testing. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-herg-screening-market-53041*